Unknown OBSERVATIONAL NCT06147960

Prognostic Role of Inhibitor of Apoptosis Protein Overexpression on Recurrence Rate in Cervical Cancer (EPIcol)

Evaluation of the Prognostic Role of Inhibitor of Apoptosis Protein Overexpression on the 24-month Recurrence Rate in Locally Advanced Cervical Cancer

Sponsor: Centre Hospitalier Universitaire de Nīmes

Conditions Apoptosis Cancer of Cervix

Interventions Immunohistochemistry

Updated 4 times since 2023 Last updated: Nov 17, 2023 Started: Nov 30, 2023 Primary completion: May 31, 2024 Completion: Nov 30, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates Apoptosis and Cancer of Cervix and is currently ongoing. Centre Hospitalier Universitaire de Nīmes leads this study, which shows 4 recorded versions since 2023 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

4 versions recorded

Jan 2026 — Present [monthly]

Unknown

Status: Not Yet Recruiting → Unknown
Sep 2024 — Jan 2026 [monthly]

Not Yet Recruiting
Jul 2024 — Sep 2024 [monthly]

Not Yet Recruiting
Dec 2023 — Jul 2024 [monthly]

Not Yet Recruiting

First recorded

Nov 2023

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Centre Hospitalier Universitaire de Nīmes
Institut du Cancer de Montpellier - Val d'Aurelle

Data source: Centre Hospitalier Universitaire de Nīmes

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.